Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
A dengue-2 live virus vaccine was tested in monkeys immune to heterologous dengue serotypes to determine if, as with wild DEN-2 virus, antibody-enhanced viraemia and seroconversion would occur. A low dose of 900 plaque-forming units (PFU) of the DEN-2/S-1 vaccine virus was inoculated subcutaneously into rhesus monkeys six months after they had received wild DEN-1, DEN-2 or DEN-3 viruses, and into non-immune monkeys. As previously reported for non-immune monkeys, there was little, if any, detectable vaccine viraemia in any of the groups of monkeys. There was no difference in seroconversion between the dengue heterologously immune (3/6) and non-immune (1/3) monkeys. These data indicated that (i) the vaccine virus may differ from the parent virus in the ability to complex with heterologous antibody and, thus, in the ability to infect Fc receptor bearing cells in monkeys; (ii) 10(3) PFU of vaccine virus is approximately the 50% infectious dose in monkeys as measured by seroconversion.
D000818:Animals; D000910:Antibodies, Heterophile / Q000096:biosynthesis*; D000914:Antibodies, Viral / Q000096:biosynthesis*; D003715:Dengue / Q000276:immunology*; D003716:Dengue Virus / Q000276:immunology*; D008253:Macaca mulatta; D008297:Male; D009500:Neutralization Tests; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014766:Viremia / Q000276:immunology*
D000910:Antibodies, Heterophile; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines